Dyne Therapeutics enters $275M loan agreement with Hercules Capital; $100M funded immediately

Dyne Therapeutics, Inc.

Initial tranche of $100M funded on June 27, 2025; additional tranches up to $175M available upon milestones and lender discretion.
Interest rate of WSJ Prime + 2.45% (floor 7.50%); maturity July 1, 2030; interest-only until July 1, 2028, extendable.
First-priority security interest on substantially all assets including IP; covenants include minimum cash and minimum net product revenue post-approval of DYNE-101 or DYNE-251.
Prepayment penalty ranges from 0.75% to 2.0% of prepaid amount; end-of-term charge of 5.5%.

item 1.01item 2.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.